What is Calcium Leucovorin?
Calcium leucovorin — also known as folinic acid or 5-formyltetrahydrofolate — is a prescription drug that has been part of American medicine for decades, yet 2026 has brought it into the national spotlight like never before. At its core, it is a reduced, active derivative of folic acid (vitamin B9) that bypasses the enzyme dihydrofolate reductase, allowing it to participate directly in critical cellular reactions involving DNA synthesis and repair. Unlike standard folic acid supplements available over the counter, leucovorin calcium requires a prescription in the United States and is administered either orally or intravenously depending on the clinical indication. The drug was originally marketed under the brand name Wellcovorin by GlaxoSmithKline beginning in 1983, though GSK discontinued production in 1997 once generic versions became available. Today in America, leucovorin is manufactured and distributed almost entirely through generic pharmaceutical producers, with the FDA allowing importation from foreign manufacturers to help stabilize supply — particularly in the wake of the dramatic prescription surge seen since late 2025.
In the United States in 2026, calcium leucovorin sits at the intersection of oncology, rare neurological disease, and intense public health policy debate. For decades its primary clinical home was in cancer treatment — specifically as a biochemical modulator of 5-fluorouracil (5-FU) in colorectal cancer regimens, and as a rescue agent after high-dose methotrexate therapy in osteosarcoma. It is also FDA-approved for treating megaloblastic anemia caused by folic acid deficiency when oral therapy is not feasible. In a landmark regulatory development, on March 10, 2026, the U.S. Food and Drug Administration granted expanded approval to leucovorin calcium tablets — specifically the Wellcovorin brand — for the treatment of cerebral folate transport deficiency due to the FOLR1 gene variant (CFD-FOLR1), marking the first FDA-authorized therapy for this ultra-rare neurological condition. This approval, combined with months of high-profile White House attention, has reshaped the public understanding of this otherwise quietly essential medication.
What Are the Benefits of Calcium Leucovorin?
Calcium leucovorin delivers measurable clinical benefits across several distinct medical contexts in the United States. In cancer care, its most impactful role is enhancing the anti-tumor activity of 5-fluorouracil (5-FU). Leucovorin is converted inside cells to 5,10-methylenetetrahydrofolate, which stabilizes the binding of fluorodeoxyuridylic acid — the active metabolite of 5-FU — to the enzyme thymidylate synthase, amplifying the drug’s cancer-killing activity. Clinical studies have demonstrated that adding leucovorin to 5-FU regimens in advanced colorectal cancer improves tumor response rates from roughly 10% with 5-FU alone to 26–43% depending on dose schedule, and extends median survival from approximately 7.7 months to 12–12.2 months. This survival benefit has made 5-FU plus leucovorin a foundational component of FOLFOX (combined with oxaliplatin) and FOLFIRI chemotherapy regimens, which are today standard-of-care protocols for colorectal cancer treatment in America. Meanwhile, as a methotrexate rescue agent, leucovorin is indispensable for osteosarcoma patients receiving high-dose methotrexate, significantly reducing life-threatening toxicities including myelosuppression, mucositis, nephrotoxicity, and gastrointestinal complications.
Beyond oncology, the 2026 FDA approval for CFD-FOLR1 underscores leucovorin’s neurological benefits. In this ultra-rare condition, a defect in the folate receptor alpha protein prevents folate from crossing the blood-brain barrier via normal pathways. Leucovorin can enter the central nervous system through an alternative transporter — the reduced folate carrier — effectively bypassing the dysfunctional pathway and restoring folate levels in the brain and cerebrospinal fluid. The FDA’s systematic review of published literature covering 46 patients with confirmed CFD-FOLR1 found that among the 27 patients treated with oral leucovorin alone, an impressive 89% (24 out of 27) demonstrated clinically meaningful neurological improvements, including reductions in seizure frequency, improvements in motor function, and enhanced communication. The benefit profile includes treating megaloblastic anemia in patients who cannot absorb folic acid orally — an underappreciated but important indication, particularly in hospitalized or critically ill patients. These overlapping benefits across oncology, hematology, and neurology make calcium leucovorin one of the most versatile prescription medications in American healthcare in 2026.
Interesting Facts About Calcium Leucovorin in the US 2026
| Fact | Detail |
|---|---|
| Original discovery | Leucovorin was first identified in 1948 as the “citrovorum factor,” an essential growth cofactor for Leuconostoc citrovorum bacteria |
| FDA approval history | The d,l-leucovorin (racemic) form was initially approved in 1952; the levo-isomer (levoleucovorin) received approval in 2008 during a leucovorin shortage |
| GSK brand history | Originally marketed as Wellcovorin by GlaxoSmithKline from 1983–1997; GSK has confirmed it has no plans to remanufacture the product in 2026 |
| Mechanism of action | Unlike folic acid, leucovorin does not require reduction by the enzyme dihydrofolate reductase, allowing it to directly enter folate-dependent biochemical reactions |
| 2026 breakthrough approval | On March 10, 2026, the FDA approved leucovorin as the first-ever treatment for cerebral folate transport deficiency due to the FOLR1 gene variant (CFD-FOLR1) |
| Ultra-rare CFD-FOLR1 prevalence | The FDA estimates CFD-FOLR1 affects fewer than 1 in 1 million people in the United States; fewer than 50 cases have ever been identified worldwide |
| Prescription surge magnitude | Leucovorin prescriptions for children aged 5–17 rose 71% above expected levels in the approximately 11 weeks following the September 22, 2025, White House briefing |
| First-week doubling | In just the second week after the White House announcement, leucovorin prescribing for children more than doubled compared to predicted baseline levels |
| First-month peak | Prescriptions were 93% above expected during the first month following the White House briefing |
| Autism diagnosis concentration | Approximately 72% of leucovorin prescriptions post-announcement were written for children with autism diagnoses — a group comprising only 4% of the pediatric population in the dataset |
| FOLFOX regimen cornerstone | Leucovorin is a core component of FOLFOX (fluorouracil + leucovorin + oxaliplatin), now the standard first-line treatment for metastatic colorectal cancer in the US |
| Colorectal cancer burden 2026 | An estimated 158,850 new colorectal cancer cases and 55,230 deaths are projected in the US in 2026 — nearly all advanced cases require leucovorin-containing chemotherapy regimens |
| CFD-FOLR1 oral treatment response | Among 27 CFD-FOLR1 patients treated with oral leucovorin alone in FDA’s literature review, 24 (89%) showed clinically meaningful neurological improvement |
| Approval evidence base | Unusually, the March 2026 FDA approval was based on a systematic review of published literature from 2009 to 2024, covering 46 patients — not traditional randomized controlled trials |
| Low-dose standard US regimen | The widely used US low-dose regimen involves leucovorin at 20 mg/m²/day plus 5-FU at 425 mg/m²/day for 5 consecutive days on a 28-day cycle |
Source: FDA Drug Approvals Database, National Cancer Institute (NCI), Brown University/Harvard Lancet Study (March 2026), FDA Press Briefing March 10, 2026, Pharmacy Times, NCBI StatPearls
The facts above paint a striking picture of calcium leucovorin as a drug that straddles two very different worlds in 2026 America. On one side, it is a decades-old oncology workhorse that underpins chemotherapy for one of the most common cancers in the country. On the other side, it has become one of the most discussed prescription drugs in America due to its intersection with autism policy, rare disease treatment, and White House communications — a combination that has few parallels in modern pharmaceutical history.
What makes these facts particularly remarkable from a clinical and public health standpoint is how the drug’s trajectory in 2026 was shaped by forces well outside the laboratory. The prescription surge data — 71% above expected baseline, with first-month peaks at 93% and first-week doubling — stands as a documented example of how high-profile government messaging can drive prescribing behavior nationwide without any new clinical trial data or formal guideline revision. The concentration of those prescriptions in children with autism diagnoses (who represent only 4% of the pediatric population yet received 72% of the new leucovorin prescriptions) highlights both the hope families place in emerging treatments and the responsibility that comes with public health communication at the highest levels of government.
Calcium Leucovorin FDA-Approved Indications in the US 2026
| Approved Indication | Route of Administration | Year Indication Established | Key Partner Drug / Condition |
|---|---|---|---|
| Colorectal cancer (advanced) — palliative treatment | IV or Oral | Pre-2000 | 5-Fluorouracil (5-FU) |
| Methotrexate rescue in osteosarcoma | IV, IM, or Oral | Pre-2000 | High-dose methotrexate |
| Inadvertent folic acid antagonist overdose | IV, IM, or Oral | Pre-2000 | Methotrexate overdose rescue |
| Megaloblastic anemia (folic acid deficiency, oral intake not feasible) | IV | Pre-2000 | Folic acid deficiency |
| Cerebral folate transport deficiency (CFD-FOLR1) | Oral | March 10, 2026 | FOLR1 gene variant |
Source: FDA Drug Label (AccessData.FDA.gov), NCI Drug Dictionary, FDA Press Release March 10, 2026
The table above represents the complete spectrum of FDA-approved uses for calcium leucovorin as of March 2026. For the first time in over two decades, the drug’s approved indications list has expanded — and the circumstances of that expansion are as clinically significant as they are historically unusual. Four of the five indications have been in place since well before the turn of the century, all rooted in leucovorin’s core biochemistry as a folate analog that works either by rescuing cells from folate antagonism or by enhancing the anti-tumor action of fluoropyrimidines. The newest indication — cerebral folate transport deficiency due to confirmed FOLR1 gene variants — represents the first time an FDA-approved therapy has existed for this condition anywhere in the world.
The regulatory pathway for that March 10, 2026 approval deserves particular attention, because it departed from standard FDA practice in a notable way. Rather than requiring randomized controlled clinical trials, the FDA accepted a systematic review of published literature spanning 2009 to 2024, encompassing 46 patients across multiple case reports. The agency noted that the treatment effects observed — 89% neurological improvement in oral leucovorin-treated patients — were large enough to overcome the inherent limitations of case-report-based evidence. This precision-indication approach, targeted at a genetically confirmed FOLR1 variant subpopulation rather than the broader CFD or autism populations discussed in earlier policy announcements, signals a cautious but real expansion of leucovorin’s recognized clinical territory in the United States.
Calcium Leucovorin Prescription Surge Statistics in the US 2026
| Time Period | Change in Leucovorin Prescriptions (Children 5–17) | Notable Context |
|---|---|---|
| Week 2 post-announcement (early October 2025) | >100% above expected (more than doubled) | Highest single-week increase recorded |
| Month 1 post-announcement (October 2025) | +93% above expected | Sustained peak demand |
| 3-month period (Oct–Dec 2025) | +71% above expected | Overall post-White House briefing average |
| % of new Rx written for autism diagnoses | 72% of total new pediatric leucovorin Rx | Autism = only 4% of pediatric dataset population |
| Acetaminophen (pregnant women, ER) | −10% below expected (first month: −16%; low point −20%) | Parallel effect from same September 22, 2025 briefing |
| Foreign manufacturer imports | FDA approved importation | To stabilize supply amid domestic shortage pressures |
| GSK Wellcovorin relaunch | Not planned | Original manufacturer has no plans to re-enter market |
Source: Brown University School of Public Health & Harvard Medical School, published in The Lancet (March 2026), DOI: 10.1016/S0140-6736(26)00243-6; FDA Press Briefing March 10, 2026
The prescription data captured in this table represents one of the most striking documented examples of federal health policy communications influencing real-world prescribing patterns in recent American medical history. A study conducted by researchers from Brown University’s School of Public Health and Harvard Medical School — published in The Lancet in March 2026 — tracked outpatient prescriptions in a large administrative database before and after the September 22, 2025 White House briefing in which President Trump and FDA Commissioner Dr. Marty Makary publicly promoted leucovorin as a potential treatment for autism. The results revealed that leucovorin prescriptions for children aged 5 to 17 climbed 71% above projected baseline levels over the three-month post-announcement window, with no new clinical trial data or formal guideline update driving this shift.
What is particularly striking — and clinically concerning from a public health perspective — is the concentration of those new prescriptions in the autism population. Children with autism diagnoses, who represent just 4% of the pediatric population in the study dataset, accounted for 72% of all new leucovorin prescriptions in that same period. The authors of the Lancet study were careful not to claim absolute causality, but noted the temporal associations were highly consistent with influence from the White House briefing on clinical decision-making. The parallel decline in acetaminophen prescriptions for pregnant women — down 10% overall and as much as 20% below expected at the low point — from the same announcement underscores that this was a broad, communications-driven shift in clinical behavior, not a coincidental trend. FDA officials responded by authorizing importation from foreign manufacturers to address the emerging supply pressure, while GSK confirmed it has no intention of re-entering the market with branded Wellcovorin.
Colorectal Cancer Burden and Leucovorin Use in the US 2026
| Statistic | 2026 Data | Source |
|---|---|---|
| Estimated new colorectal cancer cases | 158,850 (108,860 colon + 49,990 rectal) | American Cancer Society |
| Estimated colorectal cancer deaths | 55,230 | American Cancer Society / SEER |
| Daily diagnoses in adults under 65 | ~200 per day | ACS Colorectal Cancer Statistics 2026 |
| Share of CRC cases in adults under 65 | 45% (up from 27% in 1995) | ACS / CA: A Cancer Journal for Clinicians |
| Rectal cancer share of all CRC diagnoses | 32% (up from 27% in mid-2000s) | ACS Colorectal Cancer Statistics 2026 |
| Annual CRC incidence trend (overall) | −0.7% per year (2013–2022) | NCI SEER |
| Annual CRC incidence trend (under 50) | +2.9% per year (2013–2022) | NCI SEER / ACS |
| Annual CRC incidence trend (ages 50–64) | +0.4% per year (2013–2022) | NCI SEER / ACS |
| CRC death rate trend (overall) | −1.3% per year (2014–2023) | NCI SEER |
| New CRC incidence rate | 37.1 per 100,000 (age-adjusted, 2018–2022) | NCI SEER |
| CRC death rate | 12.9 per 100,000 (age-adjusted, 2019–2023) | NCI SEER |
| 5-FU + leucovorin response rate (low-dose regimen) | 43% vs. 10% with 5-FU alone | FDA-reviewed clinical trials |
| Median survival: 5-FU + leucovorin | ~12 months (vs. ~7.7 months with 5-FU alone) | FDA clinical data / CancerNetwork |
Source: American Cancer Society Cancer Facts & Figures 2026; NCI SEER Cancer Stat Facts: Colorectal Cancer (2018–2022 data); CA: A Cancer Journal for Clinicians, Colorectal Cancer Statistics 2026 (Siegel et al., published March 2, 2026); FDA Leucovorin Calcium Package Insert (AccessData.FDA.gov)
The colorectal cancer burden in 2026 is the single most important context for understanding why calcium leucovorin remains one of the most widely used oncology drugs in the United States. With an estimated 158,850 new diagnoses projected for 2026 — including roughly 200 new cases daily in adults under 65 — colorectal cancer remains the third most commonly diagnosed cancer in both men and women in America and the second leading cause of cancer-related death overall. For adults under 50, it is now the number one cause of cancer mortality, a grim milestone driven by a 2.9% annual incidence increase in that age group over the past decade. Leucovorin is a cornerstone of treatment for this disease, embedded in every major chemotherapy protocol used for advanced colorectal cancer in the country, including the dominant FOLFOX regimen (fluorouracil, leucovorin, and oxaliplatin).
The clinical data validating leucovorin’s role in colorectal cancer treatment is unambiguous and long-established. Adding leucovorin to 5-fluorouracil — the backbone of colorectal cancer chemotherapy for over four decades — increases tumor response rates from roughly 10% with 5-FU alone to 43% in the high-dose leucovorin arm, and extends median survival from approximately 7.7 months to 12 months. These numbers have been replicated across multiple randomized trials and form the basis for leucovorin’s FDA approval in this setting. The ongoing rise of colorectal cancer in younger Americans is particularly significant — with 45% of new CRC cases now occurring in people under 65 (up sharply from 27% in 1995), and rectal cancer now accounting for 32% of all colorectal cancer diagnoses (up from 27% in the mid-2000s), the demand for leucovorin-containing chemotherapy regimens in the United States shows no sign of declining.
CFD-FOLR1 Clinical Evidence and Leucovorin Efficacy in the US 2026
| Clinical Metric | Data Point | Patient Population |
|---|---|---|
| Total patients in FDA evidence review | 46 patients (identified from 2009–2024 literature) | Confirmed CFD-FOLR1, all ages |
| Patients treated with oral leucovorin alone | 27 patients | CFD-FOLR1, ages ~2 months to 33 years |
| Neurological improvement rate (oral leucovorin) | 89% (24 of 27 patients) | Clinically meaningful improvement |
| Non-responders / progressors | 3 of 27 patients | Either no change or disease progression |
| Age range at treatment initiation | ~2 months to 33 years | CFD-FOLR1 patients |
| Types of improvement observed | Reduced seizures, improved motor function, enhanced communication, behavioral gains | CFD-FOLR1 patients |
| CFD-FOLR1 estimated US prevalence | Fewer than 1 in 1,000,000 people | US population |
| Worldwide cases ever identified | Fewer than 50 cases total | Global |
| Evidence base for FDA approval | Systematic literature review (2009–2024) — no randomized controlled trials required | Published case reports with patient-level data |
| Speech improvement in CFD with autism features | Studies cited by FDA: approximately 60% improvement in speech in relevant subgroup | CFD + autism features (small studies) |
| Folic acid contraindicated in CFD-FOLR1 | Yes — standard folic acid discouraged due to competitive binding effects | CFD-FOLR1 patients |
| Earlier treatment associated with better outcomes | Yes — presymptomatic treatment of siblings after family diagnosis may prevent severe manifestations | CFD-FOLR1 |
Source: FDA Press Release and Briefing, March 10, 2026; Pharmacy Times (March 11, 2026); Fierce Pharma (March 10, 2026); FDA Wellcovorin Approval Summary
The clinical evidence table for CFD-FOLR1 reveals something genuinely remarkable: an 89% neurological improvement rate in a population where no approved treatment previously existed. For the 27 patients in the FDA’s systematic review who received oral leucovorin alone, the improvements were not marginal — they included reductions in seizure frequency or severity, meaningful gains in motor function, and improvements in communication and behavior. These are patients who, without treatment, face progressive neurological deterioration, intellectual disability, seizures, and movement disorders beginning in infancy. The breadth of improvement across such a severely affected population — spanning patients from 2 months to 33 years of age — demonstrates that leucovorin’s CNS-penetrating mechanism through the reduced folate carrier is clinically significant, even in adults whose neurological decline had already progressed.
It is worth noting what this approval does and does not mean in the broader context of 2026 public health discussions around leucovorin. The CFD-FOLR1 condition is vanishingly rare — estimated to affect fewer than 1 in a million Americans, with fewer than 50 total cases ever identified worldwide. This is categorically different from autism spectrum disorder, which affects an estimated 1 in 36 children in the United States. The FDA’s evidence review, while internally strong due to the magnitude of treatment effects, was explicitly limited to genetically confirmed FOLR1 variant patients — not patients with autism broadly, and not patients with other forms of cerebral folate deficiency caused by autoantibodies. The approval rightly represents a precision-medicine milestone for an ultra-rare condition, but the data does not support extending those conclusions to broader populations without further large, independent clinical trials.
Leucovorin as Methotrexate Rescue Agent in the US 2026
| Clinical Parameter | Established Data | Notes |
|---|---|---|
| Standard rescue dose (osteosarcoma) | 10 mg/m² IV/IM/Oral every 6 hours for 10 doses | Begins 24 hours after methotrexate initiation |
| High-intensity rescue dose | 100–150 mg/m² IV every 3 hours | When serum creatinine rises >50% over baseline |
| Serum creatinine monitoring | Required at 24-hour intervals | To assess methotrexate excretion |
| Target methotrexate level for rescue completion | Below 10⁻⁸ M (0.01 micromolar) | Before leucovorin can be discontinued |
| Drug approval year (d,l-leucovorin) | 1952 (initial US approval) | FDA |
| Drug approval year (levoleucovorin) | 2008 | Approved during leucovorin shortage |
| Osteosarcoma: methotrexate dose requiring rescue | 12 g/m² by IV infusion over 4 hours | Standard high-dose osteosarcoma protocol |
| Toxicities rescued by leucovorin | Myelosuppression, mucositis, GI toxicity, nephrotoxicity, neurotoxicity | From high-dose methotrexate |
| Folate antagonist overdose | Leucovorin rescue recommended as soon as possible, within 24 hours | Effectiveness decreases with delay |
| Hydration required alongside rescue | 3 L/day IV fluids + urinary alkalinization (pH ≥7.0) | Standard methotrexate rescue protocol |
Source: FDA Leucovorin Calcium Injection Label (AccessData.FDA.gov); NCBI StatPearls — Leucovorin (NBK553114); NCBI StatPearls — Folinic Acid (NBK545232)
The methotrexate rescue role of calcium leucovorin is one of the most protocol-critical applications of any drug in American oncology. When high-dose methotrexate is administered — as it routinely is in osteosarcoma treatment at doses of 12 g/m² — the risk of life-threatening systemic toxicity is real and well-documented. Methotrexate works by inhibiting dihydrofolate reductase, blocking DNA synthesis in both tumor cells and healthy tissues alike. Without timely leucovorin rescue, patients can experience severe myelosuppression, gastrointestinal toxicity, acute renal failure, and potentially fatal outcomes. The standard protocol — leucovorin 10 mg/m² every 6 hours beginning 24 hours after methotrexate — is one of the most carefully monitored dose-and-schedule relationships in oncology nursing, requiring daily serum methotrexate and creatinine checks to determine when rescue can safely end.
The temporal sensitivity of this rescue role is among the most clinically important facts about leucovorin in American medical practice. As the FDA label explicitly states, the drug’s effectiveness in counteracting hematologic toxicity decreases as the time interval increases between folic acid antagonist administration and leucovorin rescue initiation. This means that in cases of inadvertent methotrexate overdose, leucovorin must be started immediately — ideally within hours — and escalated to higher doses (100–150 mg/m² every 3 hours) if renal function deteriorates. The requirement for simultaneous aggressive hydration (3 liters per day) and urinary alkalinization underscores that leucovorin rescue is not a simple antidote but an intensive, multicomponent intervention requiring close inpatient monitoring. This real-world clinical complexity is largely invisible in public discourse around leucovorin in 2026, but it defines the drug’s foundational role in American cancer care.
Calcium Leucovorin and the Autism Policy Timeline in the US 2025–2026
| Date / Event | Key Development | Impact / Statistic |
|---|---|---|
| September 22, 2025 | White House briefing — President Trump and FDA Commissioner Makary publicly promote leucovorin for autism | Leucovorin prescriptions more than doubled within the first 2 weeks |
| September–December 2025 | Outpatient leucovorin prescriptions surge nationally | Overall +71% above expected levels over 11 weeks |
| October 2025 (Month 1) | Peak prescription demand reached | +93% above expected baseline |
| February 13, 2026 | American Academy of Pediatrics updates guidance | Does not recommend routine leucovorin use in autism; calls for larger independent trials |
| Early 2026 | A study supporting leucovorin for autism retracted | FDA cited this in narrowing evidence review scope |
| March 5, 2026 | Lancet study published (Brown University/Harvard) | Documents 71% surge, 72% autism diagnosis concentration, acetaminophen parallel decline |
| March 10, 2026 | FDA approves leucovorin for CFD-FOLR1 only — not for autism broadly | Estimated affected US population: <1 in 1,000,000 |
| March 10, 2026 | FDA confirms evidence insufficient for broad autism use | Notes no established figure for how many with autism have CFD |
| March 2026 | FDA authorizes foreign manufacturer imports | To address supply pressure from prescription surge |
| March 2026 | GSK confirms no plans to relaunch Wellcovorin | Generic manufacturers remain sole US suppliers |
Source: FDA Press Briefing March 10, 2026; PBS NewsHour/AP (March 10, 2026); Brown University News Release (March 5, 2026); Lancet Study (DOI: 10.1016/S0140-6736(26)00243-6); American Academy of Pediatrics Statement (February 13, 2026)
The timeline above captures one of the most remarkable chapters in recent American pharmaceutical policy. What began as a September 2025 White House press conference — in which the President and the FDA Commissioner promoted leucovorin as a potential treatment that might benefit “20, 40, 50% of kids with autism” — set off a chain of events that reshaped the drug’s public profile, created supply disruptions, and ultimately ended with a far narrower regulatory outcome than originally signaled. The documented 71% prescription surge and the 93% first-month spike are not simply statistics about drug utilization. They represent real families navigating a confusing and rapidly shifting informational landscape — many reporting difficulty filling prescriptions as pharmacies struggled with demand, and some turning to unregulated over-the-counter folate supplements as alternatives when leucovorin became hard to source.
The outcome of the FDA’s review — approving leucovorin for a condition affecting fewer than 1 in a million Americans rather than the broader autism population that had been publicly discussed — drew sharply different reactions across the medical and patient communities. For the ultra-rare CFD-FOLR1 patient population, the March 10, 2026 approval was an unambiguously historic milestone: the first FDA-approved treatment ever for their condition, backed by an 89% neurological improvement rate in the published evidence. For families of children with autism who had hoped for a recognized treatment option, it represented what autism expert Dr. David Mandell of the University of Pennsylvania described publicly as “whiplash.” The American Academy of Pediatrics, which had already updated its February 2026 guidance to withhold routine leucovorin recommendations for autism, emphasized the continued need for larger, independent randomized controlled trials before leucovorin’s potential role in the broader autism population can be scientifically established.
Disclaimer: The data reports published on The Global Files are sourced from publicly available materials considered reliable. While efforts are made to ensure accuracy, no guarantees are provided regarding completeness or reliability. The Global Files is not liable for any errors, omissions, or damages resulting from the use of these reports.